🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
20,548
Companies
1,769
Drugs tracked
4,797

Quick answer

NovaPharmaNews tracks 20,548 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

4,838 results for “SP” Clear

  1. Recombinant tissue plasminogen activator (rt-PA)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Pulmonary Thromboembolisms

    approved small molecule active

    1 trial

  2. Regadenoson

    Aspire Biopharma Holdings

    Coronary Artery Disease

    approved small molecule completed

    1 trial

  3. Regimen:TDF+3TC+EFV

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Hiv

    approved small molecule completed

    1 trial

  4. Regimen：BIC+FTC+TAF

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    HIV Infection

    approved small molecule active

    1 trial

  5. Regiocit solution pour hémofiltration

    Pari Pharma GmbH

    Adult patients hospitalized in intensive care with an indication of EER with ARC during the stay.

    approved small molecule active

    1 trial

  6. Rematazolam Besylate

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Emergence Agitation

    approved small molecule active

    1 trial

  7. Remifentanil

    Hospital Authority, Hong Kong

    Labor Pain

    approved small molecule active

    1 trial

  8. Remimazolam Besylate for Injection

    The First People's Hospital of Lianyungang

    Thoracic Surgery

    approved small molecule active

    1 trial

  9. Renin-angiotensin system blockers

    Hospital Authority, Hong Kong

    Diabetes

    approved small molecule active

    1 trial

  10. Resveratrol

    The First People's Hospital of Lianyungang

    Pancreatitis, Acute

    approved small molecule active

    1 trial

  11. Reyanning mixture

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Acute Tonsillitis

    approved small molecule active

    1 trial

  12. Rifaximin

    The First People's Hospital of Lianyungang

    IBS - Irritable Bowel Syndrome

    approved small molecule active

    1 trial

  13. Rifaximin Oral Tablet

    Hospital Authority, Hong Kong

    Irritable Bowel Syndrome With Diarrhea

    approved small molecule completed

    1 trial

  14. Rituximab

    The First People's Hospital of Lianyungang

    Hemophagocytic Lymphohistiocytosis

    approved small molecule active

    1 trial

  15. Rivaroxaban 2.5 mg

    Second Xiangya Hospital of Central South University

    Acute Coronary Syndrome

    approved small molecule completed

    1 trial

  16. Ropivacaine

    The First People's Hospital of Lianyungang

    Radius Fractures

    approved small molecule completed

    1 trial

  17. Ropivacaine

    The First People's Hospital of Lianyungang

    End Stage Renal Disease (ESRD)

    approved small molecule active

    1 trial

  18. Rosuvastatin

    The First People's Hospital of Lianyungang

    Hyperlipidemia

    approved small molecule active

    1 trial

  19. Rosuvastatin

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Infarction, Anterior Cerebral Artery

    approved small molecule active

    1 trial

  20. Rosuvastatin

    Hospital Authority, Hong Kong

    Systemic Lupus Erythematosus

    approved small molecule active

    1 trial

  21. Rosuvastatin (5mg，10mg，20mg)

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Carotid Atherosclerosis

    approved small molecule active

    1 trial

  22. Rucacuzumab plus standard therapy

    The First People's Hospital of Lianyungang

    Acute Ischemic Stroke AIS

    approved small molecule active

    1 trial

  23. Ruxolitinib

    The First People's Hospital of Lianyungang

    Safety and Efficacy

    approved small molecule active

    2 trials

  24. S-1

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 20,548 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources